Study of inotuzumab after stem cell transplant for high-risk B-cell ALL
Treatments studied
This trial tests whether a drug called inotuzumab can help prevent leukemia from returning after you have had a stem cell transplant (also called a bone marrow transplant). The study is for adults with a type of leukemia that is considered high-risk, and the drug is given after transplant to try to keep the cancer in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had a stem cell transplant (from a related or unrelated donor) and your blood counts must have recovered enough after the transplant.
- You must have a type of leukemia called B-cell acute lymphoblastic leukemia (ALL) that is CD22-positive and considered high-risk.
- You must not have had certain liver problems or active infections, and your liver and kidney function must be within the study's limits.
- You must be willing to use effective birth control during the study and for several months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
This trial studies inotuzumab, a targeted cancer drug, for people whose B-cell ALL has returned at a very low level after a bone-marrow or stem-cell transplant. If you qualify, it may help push the leukemia back under control after transplant.
This trial tests a drug called InO (inotuzumab ozogamicin) with or without donor white blood cells (DLI) for people whose B-ALL or LBL has returned after a stem cell transplant. The goal is to see if this treatment helps control the cancer with manageable side effects.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Hear when a new Acute Lymphobkastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.